Review
Medicine, General & Internal
Daniel C. Baumgart, Catherine Le Berre
Summary: This review discusses newer biologic and small-molecule therapies for inflammatory bowel disease, emphasizing the importance of achieving clinical and endoscopic remission as well as more precise molecular targeting of inflammatory cascades.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Guy G. Brusselle, Gerard H. Koppelman
Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Mehak Bassi, Siddharth Singh
Summary: Obesity is associated with inferior outcomes in patients with IBD, potentially due to its negative impact on the pharmacokinetics of biologic agents. Weight loss interventions, either through diet and lifestyle changes or weight-loss agents, may improve the response to therapy in obese IBD patients. However, implementing these interventions in IBD patients can be challenging.
Article
Immunology
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Hussain Mohammad, Preethi Cherian, Irina Al-Khairi, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Mohamed Abu-Farha, Jehad Abubaker, Fahd Al-Mulla
Summary: The study examined the immunogenicity of SARS-CoV-2 vaccines in patients with IBD on biologic therapies, revealing that the majority of patients seroconverted after receiving two doses of the vaccine.
Review
Gastroenterology & Hepatology
Ian A. Rowe, Vincent Wai-Sun Wong, Rohit Loomba
Summary: NASH has become an important cause of cirrhosis and hepatocellular carcinoma, and there are currently more than 50 therapeutic agents in clinical development. Obeticholic acid has achieved interim histological improvement in fibrosis without worsening NASH in the phase 3 REGENERATE study, and long-term clinical outcomes are being followed. It is now a timely consideration of the current situation and future direction in NASH management.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Pediatrics
Akshay Kapoor, Eileen Crowley
Summary: Therapeutic drug monitoring (TDM) has emerged as a potential tool in optimizing the efficacy of biologics for children diagnosed with inflammatory bowel disease (IBD), but the target therapeutic values for different biologics, disease states, and disease activity periods still need further definition.
FRONTIERS IN PEDIATRICS
(2021)
Article
Microbiology
Jonathan Wei Jie Lee, Damian Plichta, Larson Hogstrom, Nynke Z. Borren, Helena Lau, Sara M. Gregory, William Tan, Hamed Khalili, Clary Clish, Hera Vlamakis, Ramnik J. Xavier, Ashwin N. Ananthakrishnan
Summary: The intestinal microbiome plays a key role in determining responses to biologic therapy in inflammatory bowel disease. Microbial profiles can help predict clinical therapeutic success and guide the selection of optimal treatments for patients.
CELL HOST & MICROBE
(2021)
Article
Critical Care Medicine
Yunus Colak, Shoaib Afzal, Borge G. Nordestgaard, Peter Lange, Jorgen Vestbo
Summary: This study suggests that it is possible to identify individuals who may develop chronic obstructive pulmonary disease (COPD) at an early age. Smoking exposure is an important factor associated with the development of COPD, with smokers having a higher risk compared to non-smokers.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2021)
Review
Health Care Sciences & Services
Evanthia P. Perikleous, Paschalis Steiropoulos, Evangelia Nena, Emmanouil Paraskakis
Summary: Childhood asthma is a common and complex chronic condition in children, and the management of severe asthma remains challenging. The use of biologic agents has shown promise in treating severe childhood asthma, but long-term effects are still unclear. Further research is needed to determine the most effective biologic agents and predictors of treatment response for pediatric patients.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Dermatology
N. Geifman, N. Azadbakht, J. Zeng, T. Wilkinson, N. Dand, I. Buchan, D. Stocken, P. Di Meglio, R. B. Warren, J. N. Barker, N. J. Reynolds, M. R. Barnes, C. H. Smith, C. E. M. Griffiths, N. Peek
Summary: By analyzing changes in disease activity over time in psoriasis patients receiving biologic therapy, four distinct classes of response trajectories were identified, each associated with different clinical characteristics and potentially driven by different biological mechanisms. These subgroups may provide valuable insights for the management of psoriasis patients.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Medicine, General & Internal
Monia Marchetti, Paolo Rivela, Claudia Bertassello, Manuela Canicatti
Summary: The latest generation of treatments for B-cell chronic lymphocytic leukemia (CLL) consistently increases progression-free survival (PFS) but does not significantly impact overall survival (OS). The safety of these new therapies minimally decreases compared to standard treatments. Based on available evidence, personalized adoption of new therapies seems preferable over universal recommendations for CLL patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Brian Bressler
Summary: In the past two decades, 11 biologic agents have been approved for the treatment of moderate-to-severe inflammatory bowel disease. Anti-TNF agents are commonly used as the first biologic in clinical practice. This review examines the magnitude of benefit for each drug and how it changes with prior anti-TNF treatment, providing a reasonable approach to treatment sequences.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Nikki Duong, Payal Kakadiya, Jasmohan S. Bajaj
Summary: Hepatorenal syndrome (HRS) is a serious condition with a poor prognosis in patients with cirrhosis and ascites. This review examined randomized controlled trials on pharmacotherapy for HRS. The results suggested that norepinephrine is as effective as terlipressin for HRS reversal, and terlipressin with albumin leads to higher rates of HRS reversal compared to albumin alone.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Kabir Ahluwalia, Brandon Ebright, Kingsley Chow, Priyal Dave, Andrew Mead, Roy Poblete, Stan G. Louie, Isaac Asante
Summary: Lipidomics plays a crucial role in studying biological activity and discovering biomarkers, yet appropriate standards have not been established in this field. This review summarizes considerations for lipidomic study designs and highlights its applications in various inflammatory diseases.
Review
Rheumatology
Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin, Edoardo Savarino, Fabiana Zingone, Francesca Ometto, Marta Favero, Andrea Doria, Stephan R. Vavricka, Roberta Ramonda
Summary: Spondyloarthritis (SpA) is a group of chronic inflammatory diseases affecting the axial and peripheral joints, tendons, and entheses. Inflammatory bowel disease (IBD) is strongly associated with SpA and has significant impacts on patients' quality of life. Effective treatment requires close collaboration between gastroenterologists and rheumatologists to identify and manage joint and intestinal manifestations, and current drug options for both conditions remain limited.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis, Paolo Montuschi
EXPERT OPINION ON DRUG DISCOVERY
(2018)
Article
Biotechnology & Applied Microbiology
Giovanna Elisiana Carpagnano, Alessandro Radaeli, Donato Lacedonia, Michele Correale, Giuseppe Carpagnano, Antonio Palmiotti, Maria Pia Foschino Barbaro, Matteo Di Biase, Natale Brunetti, Giulia Scioscia, Mario Malerba
BIOMED RESEARCH INTERNATIONAL
(2018)
Article
Rheumatology
Giovanni Damiani, Paolo Daniele Maria Pigatto, Angelo Valerio Marzano, Maurizio Rizzi, Pierachille Santus, Dejan Radovanovic, Ulvi Loite, Lucio Torelli, Stephen Petrou, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Mohammad Adawi, Charlie Bridgewood, Nicola Luigi Bragazzi, Abdulla Watad, Mario Malerba
CLINICAL RHEUMATOLOGY
(2019)
Article
Pharmacology & Pharmacy
Mario Malerba, Valentina Foci, Filippo Patrucco, Patrizia Pochetti, Matteo Nardin, Corrado Pelaia, Alessandro Radaeli
FRONTIERS IN PHARMACOLOGY
(2019)
Review
Biochemistry & Molecular Biology
Gianluca Baldanzi, Mario Malerba
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Environmental Sciences
Alessandro Radaeli, Matteo Nardin, Danila Azzolina, Mario Malerba
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2019)
Review
Medicine, Research & Experimental
Gianluca Baldanzi, Beatrice Ragnoli, I. Mario Malerba
Article
Environmental Sciences
Patrizia Pochetti, Danila Azzolina, Beatrice Ragnoli, Paolo Amedeo Tillio, Vincenzo Cantaluppi, Mario Malerba
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2020)
Review
Medicine, General & Internal
Grazia Caci, Adriana Albini, Mario Malerba, Douglas M. Noonan, Patrizia Pochetti, Riccardo Polosa
JOURNAL OF CLINICAL MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Suresh Velnati, Sara Centonze, Federico Girivetto, Daniela Capello, Ricardo M. Biondi, Alessandra Bertoni, Roberto Cantello, Beatrice Ragnoli, Mario Malerba, Andrea Graziani, Gianluca Baldanzi
Summary: PKC zeta and PKC iota/lambda form the atypical protein kinase C subgroup, characterized by their regulation distinct from conventional PKCs. Both PKC zeta and PKC iota interact with phosphatidic acid and phosphatidylserine, while PKC iota uniquely binds to phosphatidylinositol-monophosphates. Additionally, phosphatidylinositol 4-phosphate specifically activates PKC iota, indicating a specific regulation of PKC iota by certain membrane lipids.
Review
Environmental Sciences
Beatrice Ragnoli, Patrizia Pochetti, Alberto Raie, Mario Malerba
Summary: OSA and insomnia are the two most common sleep disorders among the general population, with a high prevalence of insomnia symptoms in OSA patients leading to the identification of the new disorder COMISA. Combined treatment of PAP and CBTi has shown better patient outcomes, and a patient-centered approach considering individual characteristics and treatment preferences is recommended for optimal clinical management of COMISA patients. Further research is needed to fully understand the impact of these therapies on outcomes for OSA patients with comorbidity.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Environmental Sciences
Beatrice Ragnoli, Patrizia Pochetti, Patrizia Pignatti, Mariangela Barbieri, Lucrezia Mondini, Luca Ruggero, Liliana Trotta, Paolo Montuschi, Mario Malerba
Summary: Sleep health is crucial for physical and mental well-being across animal species. Recent research has shown that sleep disturbances can have detrimental effects on immune health, increasing the risk for metabolic syndrome and immune suppression. Sleep disruption and circadian misalignment have been identified as new risk factors for dysregulated metabolic physiology. This review focuses on the relationship between sleep deprivation and immunity against viruses, with a specific interest in SARS-CoV-2 infection.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Environmental Sciences
Gianluca Baldanzi, Beatrice Purghe, Beatrice Ragnoli, Pier Paolo Sainaghi, Roberta Rolla, Annalisa Chiocchetti, Marcello Manfredi, Mario Malerba
Summary: This study used an untargeted peptidomic approach to investigate the alterations of circulating peptides in COVID-19 patients. The results showed that peptide abundance is inversely correlated with disease severity and identified peptides related to inflammation, immune response, and coagulation processes. Additionally, changes in protein degradation patterns may be involved in the progression of the disease.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2023)
Article
Respiratory System
Mario Malerba, Alessandro Radaeli, Matteo Nardin, Enrico Clini, Giovanna Elisiana Carpagnano, Edoardo Sciatti, Francesca Salghetti, Ivano Bonadei, Fabio Platto, Enrico Vizzardi
CLINICAL RESPIRATORY JOURNAL
(2018)
Review
Respiratory System
Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli, Paolo Montuschi
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2018)
Review
Pharmacology & Pharmacy
Karlie R. Sharma, Christine M. Colvis, Griffih P. Rodgers, Douglas M. Sheeley
Summary: There are many genes within the druggable genome that have not been studied, and the US National Institutes of Health's program provides resources to explore these genes, with the potential for rapid impact on human health.
DRUG DISCOVERY TODAY
(2024)
Review
Pharmacology & Pharmacy
Mohammad Sameer Khan, B. H. Jaswanth Gowda, Waleed H. Almalki, Tanuja Singh, Amirhossein Sahebkar, Prashant Kesharwani
Summary: Mitochondria-specific functional liposomes hold great potential for cancer therapy. This review discusses the association between mitochondria and tumor formation, as well as the advantages of liposomes in delivering drugs to mitochondria.
DRUG DISCOVERY TODAY
(2024)
Review
Pharmacology & Pharmacy
Choong Yong Ung, Cristina Correia, Hu Li, Christopher M. Adams, Jennifer J. Westendorf, Shizhen Zhu
Summary: With increasing human life expectancy, the global medical burden of chronic diseases is growing. Chronic diseases often involve malfunctioning of multiple organs, and understanding the interorgan crosstalk is crucial to understanding the etiology of chronic diseases. Researchers have proposed the locked-state model (LoSM) and cutting-edge systems biology and artificial intelligence strategies to decipher chronic multiorgan locked states. The findings have important clinical implications for improving treatments for chronic diseases.
DRUG DISCOVERY TODAY
(2024)